Resumen

CAMPASTRI, A; BORDON, MP  y  BENDJUIA, G. Adverse drug reaction with skin signs (lichenoid rash) attributable to imatinib, and favorable response to treatment with narrowband UVB phototherapy. Rev. argent. dermatol. [online]. 2022, vol.103, n.2, pp.11-20. ISSN 1851-300X.

Imatinib is an antineoplastic agent that acts as a tyrosine kinase inhibitor. Cutaneous adverse effects are generally mild and self-limited. The lichenoid eruption due to imatinib is rare. It usually improves just with topical treatment. We present the case of a patient with a lichenoid reaction due to imatinib, refractory to treatment with topical corticosteroids, with a favorable response to narrow-band ultraviolet B phototherapy. There are no published cases to date in the literature of lichenoid eruption due to imatinib treated with phototherapy.

Palabras clave : imatinib mesylate; lichenoid eruption; phototherapy; PD1 inhibitor; adverse effects.

        · resumen en Español     · texto en Español     · Español ( pdf )